Ocular Therapeutix Advances AXPAXLI Toward Wet AMD NDA
BEDFORD, Mass. — September 15, 2026 Ocular Therapeutix, Inc. announced the successful completion of its Pre-New Drug Application (Pre-NDA)...
tyrosine kinase inhibitor
Advertisement
Taiho Oncology’s Zipalertinib Improves PFS in EGFR Lung Cancer
Princeton, New Jersey, September 15, 2026 Taiho Oncology has announced positive results from the REZILIENT3 Phase 3 trial, showing...
GSK’s Jideytro Shows 94% Response in ROS1 Lung Cancer
London, United Kingdom, September 13, 2026 GSK has announced positive registrational data from the Phase I/II ARROS-1 trial supporting...
Bayer Wins FDA Accelerated Approval for Sevabertinib
BERLIN — September 9, 2026 Bayer announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval...
Elevar Receives FDA Complete Response Letter
FORT LEE, N.J., July 10, 2026 Elevar Therapeutics announced that the U.S. Food and Drug Administration (FDA) has issued...
Advertisements
HUTCHMED Wins NMPA Approval for ORPATHYS® in Gastric Cancer
Hong Kong, Shanghai & Florham Park, N.J., July 2, 2026 HUTCHMED has achieved a major regulatory milestone after the...
Boehringer Ingelheim HERNEXEOS Approved as First Oral HER2 NSCLC Therapy
Ingelheim, Germany – May 22, 2026 Boehringer Ingelheim announced that China’s National Medical Products Administration (NMPA) has conditionally approved...
Bayer’s Sevabertinib Gets FDA Priority Review
BERLIN, Germany, May 18, 2026 Bayer has announced that the U.S. Food and Drug Administration (FDA) granted Priority Review...
Cogent Biosciences Files NDA for Bezuclastinib in GIST
WALTHAM, Mass. and BOULDER, Colo., April 1, 2026 Cogent Biosciences, Inc. has announced the successful submission of a New...
Merck to Acquire Terns to Strengthen CML Pipeline
RAHWAY, New Jersey & FOSTER CITY, California, March 25, 2026 Merck & Co. has announced a definitive agreement to...
Advertisement
